Results from our exploratory cohort of 139 patients show that five APPs - AGP, HP, AAT, CP, and ALB - are promising biomarkers to predict the beneficial response of NSCLC patients to ICI therapy. The gene discussed is CP; the disease is non-small cell lung carcinoma.